Transcript search / Intra-Cellular Therapies, Inc. / "Safety"

ITCI

Earnings call transcript

NASDAQ

2024 Q3

30 Oct 24

the greatest number of patients. We believe that the recent unprecedented efficacy and safety data for CAPLYTA in our MDD Phase III studies profoundly expands

ITCI

Earnings call transcript

NASDAQ

2024 Q2

7 Aug 24

and favorable safety and tolerability data in our Phase III studies in MDD. Pending FDA approval, we are confident in CAPLYTA's potential to become

ITCI

Earnings call transcript

NASDAQ

2024 Q1

7 May 24

the clinician-rated endpoints in this study. We continue to see a favorable safety and tolerability profile. Adverse events were similar to those seen

ITCI

Earnings call transcript

NASDAQ

2023 Q4

22 Feb 24

the continued unmet need and large opportunity in this market. Given the efficacy and safety profile to date, we are confident in CAPLYTA's future

ITCI

Earnings call transcript

NASDAQ

2023 Q2

3 Aug 23

disorders. However, adverse effects of these hallucinogenic psychedelics have raised safety issues, including abuse liability, cardiac pathology related